3.42

5.88% 0.19

After Hours: 3.38 -0.04 -1.17%

Entera Bio Ltd (ENTX)

Overview News Price History Option Chain Financials Discussions Forecast

Entera Bio Ltd stock is traded at $3.42, with a volume of 257.95K. It is up +5.88% in the last 24 hours and up +66.83% over the past month. Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Previous Close:

$3.23

Open:

$3.28

24h Volume:

257.95K

Relative Volume:

0.11

Market Cap:

$592.15M

Revenue:

$42,000

Net Income/Loss:

$-12.38M

P/E Ratio:

-12.98

EPS:

-0.2634

Net Cash Flow:

$-9.61M

1W Performance:

+17.93%

1M Performance:

+66.83%

6M Performance:

+116.46%

1Y Performance:

+76.29%

1-Day Range:

$3.20

$3.47

1-Week Range:

$2.81

$3.47

52-Week Range:

$0.91

$4.20

Entera Bio Ltd Stock (ENTX) Company Profile

Name

Entera Bio Ltd

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

972-2-532-7151

Address

KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

ENTX's Discussions on Twitter

Compare ENTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTX Entera Bio Ltd	3.42	557.52M	42,000	-12.38M	-9.61M	-0.2634
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-22-21	Initiated	Aegis Capital	Buy

Entera Bio Ltd Stock (ENTX) Latest News

Aug 20, 2026

Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1%Here's Why - MarketBeat

Aug 20, 2026

Entera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference - scanx.trade

Aug 20, 2026

Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Entera (ENTX) Results Review: EPS Misses Its Estimate; Market Move: Shares Finish 4.84% Up in the Current Update - vinanet.vn

Aug 19, 2026

Entera Bio appoints new chief medical officer - The Globe and Mail

Aug 19, 2026

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation - Sahm

Aug 19, 2026

Aug 18, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 18, 2026

Entera Bio appoints Riccardo Camisasca as chief medical officer - Investing.com

Aug 18, 2026

Entera Bio Names New Chief Medical Officer Ahead of EB613 Phase 3 Start - Minichart

Aug 18, 2026

Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com Nigeria

Aug 18, 2026

Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com Canada

Aug 18, 2026

A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan

Aug 18, 2026

Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX - MarketBeat

Aug 18, 2026

Aug 14, 2026